Compare Moderna, Inc. (MRNA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rocket Lab USA Inc — how do they compare? Moderna, Inc. trades at $136.54 (market cap $54.14B), while Rocket Lab USA Inc trades at $63.22 (market cap $40.33B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | RKLB | |
|---|---|---|
Market Cap | $54.14B | $40.33B |
Sector | Health | Technology |
52-Week High | $174.38 | $150.23 |
52-Week Low | $22.36 | $39.48 |
Enterprise Value | $50.29B | $38.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Rocket Lab (RKLB) trades at $65.87, down 56% from its 52-week high, with a bearish technical signal but strong analyst support. Q2 2026 revenue grew 62% year-over-year to $234 million, yet the company posted a net loss margin of -21.51%. Recent news highlights Neutron rocket delays to 2027 and a CFO stock sale, while Cathie Wood's ARK Invest added $45 million in shares (GuruFocus, September 7, 2026).
Outlook hinges on Neutron's successful deployment and profitability by 2028, offering high growth potential but facing execution risks and cash burn. Analysts see 78% upside to a $117.44 consensus target, though technical weakness and competitive pressures warrant caution for investors seeking space exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
